Chief Scientific Officer, Sigilon Therapeutics
David Moller joined Sigilon in January 2018 as Chief Scientific Officer. Sigilon was founded by Flagship Pioneering based on technology discovered at MIT by Robert Langer and his colleagues; the company discovers and develops immune-privileged cell implants for the treatment of chronic diseases – including hematologic, enzyme deficiency, endocrine and metabolic disorders.
In 2016-2017, David was Vice President, Business Development at Lilly – leading the Emerging Technology and Innovation team. He established Lilly’s external R&D hub in Cambridge, MA and led a global effort that focused on access to early phase external innovation across all disease areas – including novel platforms – plus leveraging flexible funding models and scientific oversight of several VC fund partnerships.
From 2006-2016 he served as VP Endocrine-CV and Clinical Investigation at Lilly, leading global discovery and development (through PhII) efforts in diabetes, cardiovascular, musculoskeletal, and urologic disease. He was also responsible for Lilly’s China R&D Centre. Moller’s team delivered several key Lilly pipeline molecules including: dulaglutide (Trulicity – FDA approved 2014), novel insulins, and a number of other PhI-III small molecules, peptides, and recombinant proteins-antibodies.
Prior to joining Lilly, Dr. Moller was Vice President, Metabolic Disorders at Merck. During a decade of work, his team discovered and delivered several additions to the pipeline; these included Sitagliptin (Januvia) and additional metabolic disease agents. Januvia sales in 2016 exceeded $4 billion.
In his R&D roles at both Lilly and Merck, David was also responsible for scientific assessments of numerous business development projects and execution of partnerships involving clinical stage programs, preclinical projects and technology platforms.
David has a B.S. from Brown University and an M.D. from University of Cincinnati. Following his fellowship at Harvard Medical School, he joined the Harvard faculty where his laboratory efforts yielded important clues to the molecular pathogenesis of metabolic syndrome, obesity and diabetes. David has published more than 130 peer-reviewed papers; his honors include election to the American Society of Clinical Investigation and the Association of American Physicians; he was also appointed adjunct professor at the Karolinska Institute.